Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
US6410524B1 · kind B1 · utility
6Cited by
4References
105Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 1999 |
| Grant date | Jun 25, 2002 |
| Priority date | — |
| Expiry date | Nov 5, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.